Cradle's AI-protein bet: $73M Series B, Novo Nordisk and J&J as customers

Cradle sells generative-AI software for protein engineering: scientists give the model experimental data, it proposes improved sequences (e.g. more heat-stable, more effective proteins), and a wet lab in Amsterdam validates results across protein types.

Language models can read proteins like code, so scientists would pay for SaaS that proposes better sequences and cuts experimental rounds — no drug company needed.

$24M Series A in 2023 (Index Ventures, Kindred Capital); $73M Series B led by IVP with Index and Kindred continuing (Nov 2024) — total funding over $100M.

Cradle appeared in 2022 as part of the wave applying language models to biology. Founder and CEO Stef van Grieken called amino-acid sequences 'an alien programming language' that AI can still parse. Its model recommends sequence changes — say, making a protein more heat-resistant — without changing its function, aiming to cut the dozens of experimental rounds pharma runs per candidate. A $24M Series A in 2023 (Index, Kindred) funded the platform and its Amsterdam laboratory.

Through 2024 Cradle grew customers across pharma and biotech, with van Grieken saying companies primarily value the acceleration and cost savings from fewer experimental runs — rounds that can cost tens or hundreds of thousands of dollars each. It commercialized the software in 2024 and passed 21 customers and 31 proteins under development, reporting R&D speedups of 1.2–12x and cost reductions up to 90%, with customers including Novo Nordisk, Johnson & Johnson Innovative Medicine, Novonesis and Grifols. In November 2024 it raised a $73M Series B led by IVP, with Index and Kindred continuing, to expand the wet lab, engineering team and go-to-market.

Scaling: as of 2024-11-26 Cradle had $100M+ total funding, named customers including Novo Nordisk, Johnson & Johnson Innovative Medicine, Novonesis and Grifols, and a stated goal of putting its software in the hands of a million scientists.

It is a clean 'pickaxe vs mine' decision: Cradle explicitly avoided drug co-development and built a royalty-free SaaS business instead.

The traction is concrete and dated: 21+ customers, 31 proteins, 1.2–12x speedups, up to 90% cost cuts (company, 2024-11-25); $73M round covered by TechCrunch (2024-11-26).

Big-name pharma customers (Novo Nordisk, J&J, Novonesis, Grifols) validate demand without requiring any drug approval.

The wet-lab strategy turns a software company into a data-compounding platform — a transferable way to keep an AI moat.

Sell the pickaxe, not the mine: Cradle chose SaaS over drug co-development; biotech adopted AI cheaply, its wet lab compounded data advantages, and pharma paid before any product shipped.

As of 2024-11-26, Cradle is scaling: it closed a $73M Series B led by IVP (total funding over $100M), was building out its Amsterdam wet lab, hiring engineers, and expanding go-to-market with a newly appointed Chief Commercial Officer, Sam Partovi, as its 40th team member. The company reports 21+ customers and 31 proteins under development, citing Novo Nordisk, Johnson & Johnson Innovative Medicine, Novonesis and Grifols among them, with R&D speedups of 1.2–12x and cost reductions up to 90%. Its goal is to put AI-powered protein engineering in every lab, beginning with a million scientists.